-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to ...
On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...
CAMBRIDGE, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...
One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...
I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...
Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...
Hosted on MSN
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer
Marty Huber, CEO, announced a strategic restructuring and reprioritization plan that includes a "reduction of about 55% of our workforce across functions, the elimination of our internal pipeline ...
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of Allocetra TM as an innovative, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results